Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have cracked a problem that has long plagued burn care: how to heal severe wounds faster without the complications of current treatments. Their answer is elegantly simple—a topical gel containing 4-aminopyridine (4-AP), an FDA-approved drug already used to treat multiple sclerosis, applied directly to the burn site.
The innovation matters because burn injuries are notoriously slow to heal. Currently, the gold standard treatment remains skin grafting, where surgeons transplant healthy tissue from another part of the patient's own body to cover the wound. But this approach carries real costs: it damages the donor site, requires large amounts of undamaged skin, and isn't always possible for patients with extensive burns. A faster, less invasive alternative could spare patients months of recovery and reduce strain on medical systems already stretched thin.
The challenge with 4-AP was always its delivery. The drug can influence keratinocytes and fibroblasts—the two cell types essential to skin repair—but systemic use carries serious risks, including seizures. Enter the gel: researchers embedded 4-AP in a laponite-gelatin formulation that delivers the drug precisely where it's needed, concentrating it at the wound site rather than exposing the whole body. As Dr. Johnson V. John, Assistant Professor at the Terasaki Institute, explained, "By delivering 4-AP directly to the wound site, we harness its regenerative potential while avoiding the systemic risks that have limited its use."
Laboratory tests revealed the gel works. In test tubes, it released 4-AP at a controlled rate, remained compatible with living cells, and achieved more than 90% wound closure within 48 hours. Animal studies told a more dramatic story. Starting at day six, treated wounds closed visibly faster than untreated controls. By day 21, the gel-treated wounds had reached near-complete closure, while control wounds remained partially open.
The biological mechanism proved just as compelling. Tissue analysis showed the gel reduced inflammation, promoted the regrowth of skin layers, and triggered new blood vessel formation. Collagen—the structural protein that gives skin its strength—surged markedly: type I collagen increased by 438% and type III collagen by 288% compared to controls. The improved ratio between collagen types also signaled better-quality tissue maturation, meaning the new skin wasn't just closing wounds faster—it was healing more completely.
What makes this advance genuinely promising is the shortcut it offers. Because 4-AP is already FDA-approved with a well-established safety profile, researchers can skip years of development spent proving a new drug is safe. The path to human trials is correspondingly shorter. "This research exemplifies our commitment to reimagining existing therapies to address medicine's most persistent challenges," said Xiling Shen, Acting Director of the Terasaki Institute.
The work, published in the journal Biomaterials, represents a meaningful shift in how burn wounds might be treated. Rather than inventing something entirely new, it shows how smart delivery technology can repurpose an existing drug to achieve what current treatments cannot. As the team moves toward further preclinical work and eventually clinical evaluation, burn patients may soon have access to a faster, less invasive path to recovery—one that could reshape how severe burn injuries are managed.